Company Active LTD

Company profile

Epitopea Limited

Home - Epitopea

Epitopea Limited is a UK company with status active founded in 2021 based in East of England.

CRN
13354764
Founded
2021
Age
5

Overview

Legal name
EPITOPEA LIMITED
Region
East of England
Registered address
SALISBURY HOUSE
STATION ROAD
CAMBRIDGE
CAMBRIDGESHIRE
UNITED KINGDOM
CB1 2LA
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

13 events
06 May
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

27 May
2026

Confirmation Statement With Updates

Confirmation-statement

CS01 | Transaction MzUyMzY3ODU0M2FkaXF6a2N4

Published 27 May 2026 09:52

22 May
2026

Change Person Director Company With Change Date

Officers

CH01 | Transaction MzUyMzI1MzgwOWFkaXF6a2N4

Published 22 May 2026 10:36

22 Apr
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

24 Feb
2025

Capital Allotment Shares

Capital

SH01 | Transaction MzQ1NjE3NjY4N2FkaXF6a2N4

Published 24 Feb 2025 04:22

31 Oct
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQ0MTYyNjQ0NGFkaXF6a2N4

Published 31 Oct 2024 03:03

27 Sep
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzNzU0MTIzM2FkaXF6a2N4

Published 27 Sep 2024 02:36

15 Aug
2024

Capital Name Of Class Of Shares

Capital

SH08 | Transaction MzQzMTk2MzUwN2FkaXF6a2N4 | Paper/PDF filed

Published 16 Aug 2024 12:40

09 Aug
2024

Capital Allotment Shares

Capital

SH01 | Transaction MzQzMTcxMTQ0MWFkaXF6a2N4

Published 09 Aug 2024 10:33

07 Aug
2024

Memorandum Articles

Incorporation

MA | Transaction MzQzMTE2NjcyOGFkaXF6a2N4 | Paper/PDF filed

Published 09 Aug 2024 10:00

23 Apr
2021

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2023
Funded years
2023, 2024
Age at first award
2 years

Projects

2024 Collaborative R&D Lead participant

Combining therapeutic vaccines and TCR-based therapeutics directed against novel antigens presented by cancer associated fibroblasts

1 Aug 2024 to 30 Apr 2026

Awarded
£501,408
Total cost £716,297

Vaccines have proven to be been humanity's most effective medical intervention acting to prepare or stimulate an immune system against the desired target. The approach has delivered generally excellent safety profiles, has a broad potential to treat a range of diseases and modern iterations of the technology (namely LNP-mRNA vaccines) have highly flexible...

2023 Collaborative R&D

Accelerating the manufacture of RNA therapies

1 Nov 2023 to 31 Jan 2025

Awarded
£44,170
Total cost £63,100

RNA therapeutics will change the standard of care for many diseases, transitioning from rare to chronic diseases, and actualize personalized medicine for millions of patients. Demand for flexible cGMP manufacturing will significantly increase across multiple RNA-therapy modalities to accelerate their route-to-patient and improve their economics. However, ...

Product types

Collaborative R&D